Navigation Links
Lafmin Morgan Joins Talecris Biotherapeutics as Vice President, U.S. Product Management

RESEARCH TRIANGLE PARK, N.C., July 8 /PRNewswire-FirstCall/ -- Talecris Biotherapeutics Holdings Corp. (Nasdaq: TLCR) today announced that Lafmin Morgan has joined the Global Commercial Operations team as vice president, U.S. Product Management.  In this role, Morgan will be responsible for product management and marketing of the company's full product portfolio in the U.S.

"Lafmin brings significant experience and leadership to Talecris and will strengthen our capabilities as we pursue the continued growth of Talecris' U.S. business," said John Perkins, executive vice president, Global Commercial Operations.

Morgan joins Talecris from GlaxoSmithKline (GSK), where he served for more than twenty years in finance, sales, commercial strategy and marketing roles across multiple therapeutic areas. His most recent role at GSK was vice president, Commercial Model Innovations, in which he led GSK's effort to build a new sales and marketing model for the company's entire U.S. business.

Prior to that, Morgan served at GSK as vice president of Sales, a position in which he managed a 2000-person sales force and served as chair of the U.S. Sales Leadership Team. He also served as vice president of Respiratory Marketing, where he implemented a marketing strategy that grew the $5 billion respiratory portfolio by 13 percent in just over one year.  

Morgan holds a Bachelor of Science in Business Administration and a Master of Business Administration from the University of North Carolina at Chapel Hill.

About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.

Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, neurology and hemostasis. For more information, please visit:

SOURCE Talecris Biotherapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Mindray Medical to Attend Morgan Stanley Global Healthcare Unplugged Conference
2. Beckman Coulter to Present at the Morgan Stanley Healthcare Unplugged Conference
3. 3SBio Inc. to Present at the Morgan Stanley Global Healthcare Unplugged Conference
4. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
5. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
6. NeurogesX to Present at Morgan Stanley Global Healthcare Unplugged Conference
7. NuVasive to Present at Morgan Stanley Global Healthcare Unplugged Conference
8. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
9. Inverness Medical Innovations to Present at the Morgan Stanley Global Healthcare Unplugged Conference on September 9, 2008
10. Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference
11. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
Post Your Comments:
(Date:6/27/2016)... PHILADELPHIA , June 27, 2016  Liquid ... today announced the funding of a Sponsored Research ... study circulating tumor cells (CTCs) from cancer patients.  ... changes in CTC levels correlate with clinical outcomes ... therapies. These data will then be employed to ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: ... for financial services, but it also plays a fundamental part ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
Breaking Biology News(10 mins):